Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Donor Regulatory T Cells in Treating Patients With Visceral Acute Graft-versus-Host Disease After Stem Cell Transplant

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02526329
Recruitment Status : Suspended (Logistics)
First Posted : August 18, 2015
Last Update Posted : April 22, 2019
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Everett Meyer, Stanford University

Brief Summary:
This phase I trial studies the side effects and best dose of donor regulatory T cells in treating patients with graft-versus-host disease affecting the liver or gastrointestinal organs (visceral) within 100 days (acute) after undergoing a stem cell transplant. Graft-versus-host disease occurs when donor immune cells infused in a stem cell transplant attack the gut, skin, liver, or other organ systems of the patient. Regulatory T cells are a type of immune cell that may be able to reduce the attack of the donor's immune cells on the patient's normal cells and help treat graft-vs-host disease.

Condition or disease Intervention/treatment Phase
Graft Versus Host Disease Biological: donor regulatory T lymphocytes Other: laboratory biomarker analysis Phase 1

Detailed Description:

PRIMARY OBJECTIVES:

I. Determine the safety and feasibility of donor T regulatory (Treg) cell infusions in subjects with visceral acute graft-versus-host disease (aGVHD) and incidence of dose limiting toxicities (DLTs) graded according to the Common Terminology Criteria for Adverse Events (CTCAE version 4 [v.4]) with a focus on infusion reactions within 24 hours, respiratory distress within 72 hours of infusion and all-cause mortality within 28 days of infusion.

SECONDARY OBJECTIVES:

I. Determine the quantitative blood Treg cell changes following the cell infusions.

II. Assess dosing requirements and treatment response rates to primary steroid, secondary and tertiary immunosuppressive therapy.

III. Post-transplant day +100 and day +180 survival. IV. Post-transplant incidence of chronic graft-versus-host disease (GVHD) at day +180.

OUTLINE: This is a dose-escalation study.

Patients receive donor regulatory T lymphocytes intravenously (IV) over 5 minutes or less on day 0. Some patients receive a second infusion of frozen donor regulatory T lymphocytes 5-7 days after the initial infusion or 2 additional infusions separated by 5-7 days.

After completion of study treatment, patients are followed up weekly until day 28 and then on days 100 and 180.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 12 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1 Single Center Safety and Feasibility Study of Primary T Regulatory Cell Therapy to Treat Visceral Acute Graft-versus-Host Disease Following Hematopoietic Cell Transplantation
Actual Study Start Date : August 2015
Estimated Primary Completion Date : December 2023
Estimated Study Completion Date : December 2024


Arm Intervention/treatment
Experimental: Treatment (donor regulatory T lymphocytes)
Patients receive donor regulatory T lymphocytes intravenously (IV) over 5 minutes or less on day 0. Some patients receive a second infusion of frozen donor regulatory T lymphocytes 5-7 days after the initial infusion or 2 additional infusions separated by 5-7 days.
Biological: donor regulatory T lymphocytes
Given IV
Other Name: donor CD4+CD25+FoxP3+ T cells

Other: laboratory biomarker analysis
Correlative studies




Primary Outcome Measures :
  1. Incidence of grade 3 infusion reaction within 24 hours of infusion [ Time Frame: 24 hours ]
    Dose-limiting toxicity will be defined as CTCAE Grade 3 or higher cytokine/release syndrome/acute infusion reaction within 24 hours after Treg cell infusion. The rates of defined DLTs will be calculated and the one-sided upper 80%, 90%, and 95% confidence limits calculated.


Secondary Outcome Measures :
  1. Incidence of grade 3 or higher non-GVHD infusion-related adverse events [ Time Frame: Up to day 28 ]
    Incidence of grade 3 or higher non-GVHD infusion-related adverse events according to the CTCAE v4 that are not anticipated following HCT will be reported

  2. Grade 4 (life threatening) or 5 (fatal) adverse events [ Time Frame: 28 days ]
    Grade 4 (life threatening) or 5 (fatal) adverse events within after 28 days of Treg infusion that were otherwise unexpected in the immediate post transplant setting will be reported

  3. Grade 4 (life threatening) respiratory distress [ Time Frame: 72 hours ]
    Grade 4 (life threatening) respiratory distress within 72 hours of Treg infusion will be reported

  4. Change in blood Treg cell numbers following the infusions [ Time Frame: Baseline to up to day 28 ]
    The change in Treg cell counts from baseline to post infusion will be depicted in boxplots of both relative proportion and absolute numbers. Mean log (fold change) and confidence intervals will be calculated. The confidence intervals will be used to test the hypotheses of no change from baseline to post infusion.

  5. Overall survival (OS) [ Time Frame: Day 100 ]
    The OS will be estimated by the Kaplan-Meier product-limit method, with standard confidence limits.

  6. Incidence of cGVHD. [ Time Frame: 180 days ]
    Incidence of cGVHD will be reported at Post HCT day +180



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Visceral aGVHD defined as: at least stage III/IV acute liver or stage II/III gastrointestinal (GI) GVHD by clinical criteria and/or GI and/or liver biopsy confirmation showing no alternative explanation for symptoms of GVHD
  • Ability to understand and willingness to sign a written informed consent form
  • Must have a 7/8 or 8/8 or haploidentical related donor matched at the human leukocyte antigen (HLA)-A, B, C, DRB1 who was evaluated and provided the donor transplant graft
  • Myeloablative or non-myeloablative allogeneic hematopoietic cell transplantation
  • Karnofsky performance status >= 50
  • DONOR: Age >= 18 to =< 77 years old
  • DONOR: Karnofsky performance status of >= 70% defined by institutional standards
  • DONOR: Must be the same sibling donor from whom the recipient's blood and marrow graft was collected for the original allogeneic transplant that is HLA 7/8 or 8/8 or haploidentical matched at the HLA-A, B, C, and DRB1
  • DONOR: Serologies for human immunodeficiency virus (HIV) antigen (Ag), HIV 1 and HIV 2 antibody (Ab), human T-cell lymphotropic virus (HTLV) 1 and HTLV 2 Ab, hepatitis B surface antigen (sAg) or polymerase chain reaction (PCR)+, or hepatitis C Ab or PCR+, syphilis (Treponema) screen and HIV 1 and hepatitis C by NAT (nucleic acid testing) have been collected prior to apheresis
  • DONOR: Female donors of child-bearing potential must have a negative serum or urine beta-human chorionic gonadotropin (HCG) test within two weeks of apheresis
  • DONOR: Capable of undergoing leukapheresis, have adequate venous access, and be willing to undergo insertion of a central catheter should leukapheresis via peripheral vein be inadequate
  • DONOR: Donor selection will be in compliance with 21 Code of Federal Regulations (CFR) 1271

Exclusion Criteria:

  • Uncontrolled infections not responsive to antimicrobial therapy requiring intensive critical care
  • Progressive malignant disease, including post-transplant lymphoproliferative disease unresponsive to therapy
  • Cytomegalovirus colitis or enteritis as defined by cytomegalovirus (CMV) shell vial or culture positivity from endoscopic biopsy the discretion of the treating physician based upon PCR positivity, clinical presentation and histology
  • Respiratory insufficiency with oxygen requirement > 4 L nasal cannula
  • Multi-organ failure
  • DONOR: Evidence of active infection or viral hepatitis
  • DONOR: HIV positive
  • DONOR: Pregnant donor
  • DONOR: Factors which place the donor at increased risk for complications from leukapheresis

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02526329


Locations
Layout table for location information
United States, California
Stanford University Hospitals and Clinics
Stanford, California, United States, 94305
Sponsors and Collaborators
Everett Meyer
National Cancer Institute (NCI)
Investigators
Layout table for investigator information
Principal Investigator: Everett Meyer Stanford University Hospitals and Clinics
Layout table for additonal information
Responsible Party: Everett Meyer, Assistant Professor of Medicine, Stanford University
ClinicalTrials.gov Identifier: NCT02526329    
Other Study ID Numbers: IRB-30861
NCI-2014-01609 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
IRB-30861 ( Other Identifier: Stanford IRB )
BMT267 ( Other Identifier: OnCore )
First Posted: August 18, 2015    Key Record Dates
Last Update Posted: April 22, 2019
Last Verified: April 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Graft vs Host Disease
Immune System Diseases